News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2024 Faster CAC Progression After Menopause May Warrant Intensified Therapy L.A. McKeown April 04, 2024
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ACC 2021 Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia Yael L. Maxwell May 16, 2021
News Conference News ACC 2021 Social Determinants of Health Tied to Fewer COVID-19 Precautions in CVD Patients Caitlin E. Cox May 07, 2021
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020
News Conference News ESC 2019 Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories Yael L. Maxwell September 06, 2019
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News SCCT 2017 Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking Yael L. Maxwell July 13, 2017
News Conference News SCCT 2017 Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See? Yael L. Maxwell July 10, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News You Can’t Blame Your Genes: Healthy Lifestyle Halves Genetic Risk of CAD Shelley Wood November 15, 2016